Project Grant R01HL180515
Award Date 9/5/25
Completion Date 5/31/30
Dollars Obligated $552K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
- This federal Project Grant award of $680,583.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover genetic modifiers and novel therapies for anthracycline-induced cardiotoxicity. The study aims to use zebrafish models to test candidate genes identified from human genome-wide association studies, as well as explore the role of aging-associated epicardial remodeling in cardiotoxicity. Key areas of focus include...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $136,804 to the University of Illinois to investigate the role of the GCN2 protein in ponatinib-induced cardiotoxicity. The 5-year research plan aims to enhance the principal investigator's expertise in cardio-oncology through training in sequencing technology, stem cell biology, mitochondrial biology, and oncology. The research utilizes human induced...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
- This federal Project Grant award, valued at $695,997.00 and awarded on Aug 18, 2025, supports research conducted by Mayo Clinic Arizona under the Cardiovascular Diseases Research program (CFDA 93.837) administered by the National Heart, Lung, and Blood Institute. The research aims to investigate the role of the Programmed Cell Death 4 (PDCD4) gene in mitigating doxorubicin-induced cardiotoxicity, a common side effect of anthracycline chemotherapy drugs. The project utilizes a juvenile mouse...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is for a targeted approach to treat immunotherapy-induced myocarditis (inflammation of the heart) using CXCR3 blockade. The total funding amount is $773,843, awarded on September 19, 2025, with an ultimate completion date of May 31, 2029. The key products and services to be delivered under this grant include: Validating the role of CXCR3-positive CD8+ T cells and...
- This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...
- The federal Project Grant award of $731,827 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is supporting research conducted by the J. David Gladstone Institutes in San Francisco, CA to investigate the mechanisms of oxygen toxicity. The key objectives include: 1) testing whether specific molecular pathways (diphthamide synthesis, de novo purine synthesis, and mitochondrial electron transport chain) are necessary and sufficient for impaired cell...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
- This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...
- This Project Grant award, valued at $415,500.00 and awarded by the National Cancer Institute under the federal Cancer Treatment Research program (CFDA 93.395), is funding research into peptide-doxorubicin (DOX) conjugates to mitigate cardiotoxicity and overcome drug resistance in cancer. The key objectives are to investigate the mechanisms by which five peptide-DOX conjugates can effectively target and overcome DOX-resistant cancer cells while reducing cardiotoxicity, in order to enhance...